Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma

This study is currently recruiting participants.
Verified March 2014 by University of Nebraska
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Julie M Vose, MD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT01431209
First received: September 5, 2011
Last updated: March 8, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2025
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)